Cardiol Historical Financial Ratios
| CRDL Stock | CAD 1.93 0.10 4.93% |
Cardiol Therapeutics is presently reporting on over 90 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0, PTB Ratio of 2.38 or Days Sales Outstanding of 1.5 K will help investors to properly organize and evaluate Cardiol Therapeutics financial condition quickly.
Cardiol |
About Cardiol Financial Ratios Analysis
Cardiol TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Cardiol Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Cardiol financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Cardiol Therapeutics history.
Cardiol Therapeutics Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Cardiol Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Cardiol Therapeutics sales, a figure that is much harder to manipulate than other Cardiol Therapeutics Class multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Ptb Ratio
Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.Book Value Per Share
The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.Operating Cash Flow Per Share
A measure of the cash generated from a company's normal business operations per share, indicating how much cash is generated from a company's business operations on a per-share basis.Most ratios from Cardiol Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Cardiol Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardiol Therapeutics Class. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. At this time, Cardiol Therapeutics' Graham Number is very stable compared to the past year. As of the 13th of December 2024, Shareholders Equity Per Share is likely to grow to 0.64, while PTB Ratio is likely to drop 2.38.
| 2023 | 2024 (projected) | Days Sales Outstanding | 1.7K | 1.5K | PTB Ratio | 2.51 | 2.38 |
Cardiol Therapeutics fundamentals Correlations
Click cells to compare fundamentals
Cardiol Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Cardiol Therapeutics fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Ptb Ratio | 8.06 | 6.25 | 1.32 | 0.83 | 2.51 | 2.38 | |
| Book Value Per Share | 1.45 | 0.57 | 0.44 | 1.76 | 0.84 | 0.64 | |
| Free Cash Flow Yield | (0.0998) | (0.11) | (0.23) | (0.63) | (3.56E-4) | (3.74E-4) | |
| Operating Cash Flow Per Share | (0.71) | (0.44) | (0.31) | (0.54) | (3.91E-4) | (4.1E-4) | |
| Capex To Depreciation | 2.82 | 0.18 | 0.0586 | 0.34 | 2.59E-4 | 2.46E-4 | |
| Pb Ratio | 8.06 | 6.25 | 1.32 | 0.83 | 2.51 | 2.38 | |
| Free Cash Flow Per Share | (0.46) | (0.31) | (0.55) | (0.44) | (3.92E-4) | (4.11E-4) | |
| Roic | (0.95) | (1.55) | (0.47) | (0.36) | (1.05) | (1.1) | |
| Net Income Per Share | (0.54) | (0.69) | (0.57) | (0.18) | (0.44) | (0.46) | |
| Payables Turnover | 0.0427 | 268.26 | 129.67 | 0.0263 | 0.0237 | 0.0225 | |
| Cash Per Share | 0.27 | 0.47 | 1.94 | 0.95 | 0.54 | 0.62 | |
| Pocfratio | (10.39) | (9.04) | (4.28) | (1.58) | (2.8K) | (2.7K) | |
| Capex To Operating Cash Flow | (0.0373) | (0.00442) | (5.48E-4) | (0.002745) | (0.002554) | (0.002682) | |
| Pfcf Ratio | (10.02) | (9.0) | (4.27) | (1.58) | (2.8K) | (2.7K) | |
| Days Payables Outstanding | 8.5K | 1.36 | 2.81 | 13.9K | 12.5K | 13.1K | |
| Income Quality | 0.83 | 0.45 | 0.74 | 0.88 | 8.95E-4 | 8.5E-4 | |
| Roe | (0.95) | (1.56) | (0.32) | (0.22) | (1.0) | (1.05) | |
| Ev To Operating Cash Flow | (9.8) | (7.53) | (0.72) | 0.6 | (1.4K) | (1.4K) | |
| Pe Ratio | (8.46) | (4.02) | (4.07) | (3.74) | (2.52) | (2.65) | |
| Return On Tangible Assets | (0.94) | (1.34) | (0.28) | (0.19) | (0.77) | (0.81) | |
| Ev To Free Cash Flow | (9.45) | (7.49) | (0.72) | 0.6 | (1.4K) | (1.4K) | |
| Earnings Yield | (0.23) | (0.12) | (0.25) | (0.27) | (0.4) | (0.42) | |
| Intangibles To Total Assets | 0.0354 | 0.0292 | 0.004316 | 0.004753 | 0.005732 | 0.005445 | |
| Net Debt To E B I T D A | 0.5 | 0.68 | 2.18 | 1.93 | 1.25 | 1.03 | |
| Current Ratio | 20.81 | 5.94 | 7.53 | 6.27 | 4.36 | 4.14 | |
| Tangible Book Value Per Share | 1.41 | 0.55 | 0.43 | 1.76 | 0.83 | 0.63 | |
| Shareholders Equity Per Share | 1.45 | 0.57 | 0.44 | 1.76 | 0.84 | 0.64 | |
| Capex Per Share | 8.97E-4 | 0.0164 | 0.00136 | 2.99E-4 | 0.001195 | 1.0E-6 | |
| Graham Net Net | 0.29 | 0.39 | 1.68 | 0.8 | 0.41 | 0.55 | |
| Enterprise Value Over E B I T D A | (8.24) | (3.39) | (0.44) | 0.53 | (1.3) | (1.36) | |
| Price Earnings Ratio | (8.46) | (4.02) | (4.07) | (3.74) | (2.52) | (2.65) | |
| Price Book Value Ratio | 8.06 | 6.25 | 1.32 | 0.83 | 2.51 | 2.38 |
Pair Trading with Cardiol Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cardiol Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cardiol Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Cardiol Stock
Moving against Cardiol Stock
The ability to find closely correlated positions to Cardiol Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cardiol Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cardiol Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cardiol Therapeutics Class to buy it.
The correlation of Cardiol Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cardiol Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cardiol Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cardiol Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardiol Therapeutics Class. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.